Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab After B Cell Depletion in Systemic Lupus Erythematosus
2015-005543-14Phase 2Unknown
- Sponsor
- University College London
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of belimumab in systemic lupus erythematosus (SLE), sponsored by University College London. Primary endpoint: Anti-dsDNA antibody levels at 52 weeks. Status: unknown.
02
Drugs
belimumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2015-005543-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005543-14.